Three are better than one-increasing HBV seroprotection by a tri-antigenic vaccine
- PMID: 33989540
- DOI: 10.1016/S1473-3099(20)30845-8
Three are better than one-increasing HBV seroprotection by a tri-antigenic vaccine
Conflict of interest statement
FvB reports research grants from Ipsen, Roche, and Gilead Sciences; consulting fees from Ipsen, Janssen, and MSD; speakers bureaus from Ipsen, MSD, and Janssen; support for attending meetings from Ipsen, Gilead Sciences, and Bayer Healthcare; and participation on advisory boards for Ipsen, AstraZeneca, and Janssen, within the past 36 months. TB declares no competing interests.
Comment on
-
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.Lancet Infect Dis. 2021 Sep;21(9):1271-1281. doi: 10.1016/S1473-3099(20)30780-5. Epub 2021 May 11. Lancet Infect Dis. 2021. PMID: 33989539 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
